Islam Sk Injamamul, Sanjida Saloa, Ahmed Sheikh Sunzid, Almehmadi Mazen, Allahyani Mamdouh, Aljuaid Abdulelah, Alsaiari Ahad Amer, Halawi Mustafa
The International Graduate Program of Veterinary Science and Technology (VST), Department of Veterinary Microbiology, Faculty of Veterinary Science and Technology, Chulalongkorn University, Bangkok 10330, Thailand.
Department of Environmental Science and Technology, Faculty of Applied Science and Technology, Jashore University of Science and Technology, Jashore 7408, Bangladesh.
Vaccines (Basel). 2022 Oct 7;10(10):1669. doi: 10.3390/vaccines10101669.
Chagas disease is a tropical ailment indigenous to South America and caused by the protozoan parasite , which has serious health consequences globally. Insect vectors transmit the parasite and, due to the lack of vaccine availability and limited treatment options, we implemented an integrated core proteomics analysis to design a reverse vaccine candidate based on immune epitopes for disease control. Firstly, core proteomics was used to identify immunodominant epitopes. Therefore, we designed the vaccine sequence to be non-allergic, antigenic, immunogenic, and to have better solubility. After predicting the tertiary structure, docking and molecular dynamics simulation (MDS) were performed with TLR4, MHC-I, and MHC-II receptors to discover the binding affinities. The final vaccine design demonstrated significant hydrogen bond interactions upon docking with TLR4, MHC-I, and MHC-II receptors. This indicated the efficacy of the vaccine candidate. A server-based immune simulation approach was generated to predict the efficacy. Significant structural compactness and binding stability were found based on MDS. Finally, by optimizing codons on K12, a high GC content and CAI value were obtained, which were then incorporated into the cloning vector pET2+ (a). Thus, the developed vaccine sequence may be a viable therapy option for Chagas disease.
恰加斯病是一种原产于南美的热带疾病,由原生动物寄生虫引起,在全球范围内具有严重的健康后果。昆虫媒介传播这种寄生虫,由于缺乏可用疫苗且治疗选择有限,我们实施了一项综合核心蛋白质组学分析,以设计一种基于免疫表位的反向疫苗候选物用于疾病控制。首先,利用核心蛋白质组学来鉴定免疫显性表位。因此,我们将疫苗序列设计为无过敏反应、具有抗原性、免疫原性且具有更好的溶解性。在预测三级结构后,与TLR4、MHC-I和MHC-II受体进行对接和分子动力学模拟(MDS)以发现结合亲和力。最终的疫苗设计在与TLR4、MHC-I和MHC-II受体对接时显示出显著的氢键相互作用。这表明了候选疫苗的有效性。生成了一种基于服务器的免疫模拟方法来预测疗效。基于MDS发现了显著的结构紧凑性和结合稳定性。最后,通过在K12上优化密码子,获得了高GC含量和CAI值,然后将其整合到克隆载体pET2+(a)中。因此,所开发的疫苗序列可能是恰加斯病的一种可行治疗选择。